IMMUNEONCO-B(01541): The phase Ib/IIa clinical trial of IMM0306 in combination with lenalidomide for the treatment of chronic lymphocytic leukemia has successfully recruited 27 evaluable patients as of October 26th.

IMMUNEONCO-B (01541) announced that the Phase Ib/IIa clinical trial of IMM0306 in combination with lenalidomide for the treatment of chronic lymphocytic leukemia has recruited a total of 27 evaluable patients (25 follicular lymphoma (FL) patients and 2 marginal zone lymphoma (MZL) patients) as of October 26, 2024. The efficacy data for relapsed or refractory (R/R) FL patients as of October 26, 2024 are shown below: As of October 26, 2024, the overall response rate (ORR) and complete response rate (CRR) in 25 evaluable R/R FL patients were 84.0% and 40.0%, respectively, while the overall response rate in the 2 evaluable R/R MZL patients reached 100.0%, indicating a promising efficacy signal. The study is currently actively recruiting and ongoing. IMM0306, independently developed by the group, is a dual-specificity molecule targeting cluster of differentiation 47 (CD47) and cluster of differentiation 20 (CD20). It is the world's first CD47 and CD20 dual-targeted dual-specificity molecule to enter clinical trials. Through enhanced antibody-dependent cellular phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC), IMM0306 can simultaneously bind to CD47 and CD20 expressed on malignant B cells, with higher affinity for CD20 than CD47, thus improving treatment efficacy.